{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-071261","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2024-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.050186+00:00","generated_at":"2026-06-01T04:41:55.226562+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Nuvectis Pharma stockholders re-elect directors and ratify auditor at 2024 annual meeting","bullets":["Kenneth Hoberman elected Class II director with 8,026,155 votes for, 809,797 against.","Matthew Kaplan elected Class II director with 8,502,724 votes for, 333,228 against.","Ratification of Kesselman & Kesselman as auditor approved: 12,055,252 for, 31,882 against.","Voting based on 12,227,134 shares present (66.55% of outstanding) on record date April 15, 2024.","All proposals as described in definitive proxy statement filed April 29, 2024 were approved."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-071261","json":"https://secwatch.observer/filing/0001104659-24-071261.json","markdown":"https://secwatch.observer/filing/0001104659-24-071261.md","text":"https://secwatch.observer/filing/0001104659-24-071261.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465924071261/0001104659-24-071261-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465924071261/tm2417208d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:41:55.226562+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}